3 news items
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
TAK
17 Jun 24
in the responder rate, measures of caregiver and clinician global impression of improvement, and seizure intensity and duration scales over the 16
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK
17 Jun 24
impression of improvement, and seizure intensity and duration scales over the 16-week treatment period (all p-values ≤ 0.008
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
SNY
TAK
15 May 24
6–16 in settings with high dengue burden and transmission intensity.
Related
- Prev
- 1
- Next